COMMUNIQUÉS West-GlobeNewswire

Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline

26/11/2018 - 14:00

Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operations Parag Meswani, Pharm.D., formerly head of U.S. [...]

CareDx Announces Full Repayment of its Outstanding Debt

26/11/2018 - 14:00

Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet BRISBANE, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and [...]

HempAmericana Estimates $1M Revenue Yield from First Hemp Harvest at Its Union Farm Facility

26/11/2018 - 14:00

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – HempAmericana, Inc. (OTC: HMPQ) (“HempAmericana” or the “Company”) is excited to announce production results and revenue estimates following the first [...]

Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019

26/11/2018 - 14:00

PLYMOUTH MEETING, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that three recent published studies of its DNA-Encoded monoclonal antibody (dMAb™) technology showed [...]

Spectral Announces Publication of the post hoc analysis of EUPHRATES trial in Intensive Care Medicine

26/11/2018 - 14:00

TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT) , a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]

Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

26/11/2018 - 13:50

Company to provide regulatory filing status update FRAMINGHAM, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid [...]

CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments

26/11/2018 - 13:50

CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor PLEASANTON, Calif. and HANGZHOU, China, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT) and Zhejiang [...]

Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

26/11/2018 - 13:30

EWING, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 30 th Annual Piper Jaffray Healthcare [...]

CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

26/11/2018 - 13:25

OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement [...]

Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

26/11/2018 - 13:05

SAN DIEGO and TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of [...]

Resonant Inc. Initiates $4 Million Stock Repurchase Program

26/11/2018 - 13:05

GOLETA, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, announced its [...]

Form 8 (DD) - Shire plc

26/11/2018 - 13:00

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1

26/11/2018 - 13:00

BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Repeat: Canopy Rivers Secures International Joint Venture Rights and Accelerates Development at PharmHouse

26/11/2018 - 13:00

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV: RIV) is pleased to announce it has, [...]

Zafgen Provides Update on Investigational New Drug Application for ZGN-1061

26/11/2018 - 13:00

BOSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]

Aleafia Posts Record Revenue in Q3 2018, 36% Increase Over Previous Quarter

26/11/2018 - 13:00

First Quarter of Profitability for Clinic and Cannabis Product Divisions 99% of 98,000 kg Annual Cannabis Production Capacity to Come Online in 2019 TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: [...]

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome

26/11/2018 - 13:00

- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo - - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome - - EPIDIOLEX [...]

Aravive Announces Participation at Upcoming Investor Conference

26/11/2018 - 13:00

HOUSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference [...]

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

26/11/2018 - 12:30

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune ® , a novel, versatile, multi [...]